| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Purine nucleoside metabolism pathways, including DNA synthesis. As a purine nucleoside analog, 2',3',5'-Tri-O-acetyl-6-chloroguanosine is incorporated into DNA or RNA, disrupting nucleic acid synthesis. The compound targets rapidly dividing cells, particularly lymphoid malignancies. The acetyl groups may improve cellular uptake and stability.
|
|---|---|
| ln Vitro |
2',3',5'-Tri-O-acetyl-6-chloroguanosine demonstrates activity as a purine nucleoside analog in cellular assays. Purine nucleoside analogs have broad-spectrum anticancer effects. The compound inhibits DNA synthesis and induces apoptosis in cancer cells. Detailed IC50 values against specific cancer cell lines have not been disclosed in publicly available literature.
|
| ln Vivo |
In vivo activity of 2',3',5'-Tri-O-acetyl-6-chloroguanosine has not been extensively characterized in published literature. As a purine nucleoside analog, it would be expected to have antitumor activity in animal models of lymphoid malignancies. In vivo studies would be needed to evaluate its therapeutic potential. Currently, limited in vivo data are available.
|
| Enzyme Assay |
In vitro assays for purine nucleoside analogs typically involve measuring inhibition of DNA synthesis using radiolabeled thymidine incorporation. The compound is incubated with cancer cells at varying concentrations, and incorporation of labeled nucleosides is measured. Cell viability is assessed by MTT or CellTiter-Glo assays. Apoptosis is evaluated by caspase activation or Annexin V staining.
|
| Cell Assay |
Cells (e.g., lymphoid malignancy cell lines such as Jurkat, Raji, or other cancer cell lines) are cultured and treated with 2',3',5'-Tri-O-acetyl-6-chloroguanosine at concentrations typically ranging from 0.1–100 μM for 24–72 hours. DNA synthesis inhibition is measured by BrdU incorporation. Cell viability is assessed by standard assays. Apoptosis is evaluated by flow cytometry or Western blot for cleaved caspases.
|
| Animal Protocol |
In vivo animal studies for 2',3',5'-Tri-O-acetyl-6-chloroguanosine have not been reported in publicly available literature. The compound is primarily used as a research tool for nucleoside analog studies. Future studies in xenograft models of lymphoid malignancies would be needed to evaluate in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2',3',5'-Tri-O-acetyl-6-chloroguanosine have not been published. The compound has a molecular weight of 427.79 and formula C16H18ClN5O7. The acetyl groups may improve cellular permeability and stability. In vivo PK parameters such as half-life, bioavailability, and tissue distribution have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data for 2',3',5'-Tri-O-acetyl-6-chloroguanosine have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling nucleoside analogs should be observed.
|
| References |
[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88.
|
| Additional Infomation |
2',3',5'-Tri-O-acetyl-6-chloroguanosine (CAS: 16321-99-6, molecular formula C16H18ClN5O7, molecular weight 427.79) is a purine nucleoside analog. It has broad antitumor activity targeting indolent lymphoid malignancies. It is not in clinical trials and has no regulatory approval. The compound is supplied as a research-grade nucleoside analog for laboratory use only.
|
| Molecular Formula |
C16H18CLN5O7
|
|---|---|
| Molecular Weight |
427.80
|
| Exact Mass |
427.089
|
| CAS # |
16321-99-6
|
| PubChem CID |
10788628
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.7g/cm3
|
| Boiling Point |
637ºC at 760mmHg
|
| Melting Point |
146.0 to 150.0 °C
|
| Flash Point |
339ºC
|
| Vapour Pressure |
4E-16mmHg at 25°C
|
| Index of Refraction |
1.69
|
| LogP |
0.967
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
29
|
| Complexity |
655
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
ClC1C2=C(N=C(N([H])[H])N=1)N(C([H])=N2)[C@@]1([H])[C@@]([H])([C@@]([H])([C@@]([H])(C([H])([H])OC(C([H])([H])[H])=O)O1)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O
|
| InChi Key |
HLVGVJFVAKPFOZ-SDBHATRESA-N
|
| InChi Code |
InChI=1S/C16H18ClN5O7/c1-6(23)26-4-9-11(27-7(2)24)12(28-8(3)25)15(29-9)22-5-19-10-13(17)20-16(18)21-14(10)22/h5,9,11-12,15H,4H2,1-3H3,(H2,18,20,21)/t9-,11-,12-,15-/m1/s1
|
| Chemical Name |
[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2-amino-6-chloropurin-9-yl)oxolan-2-yl]methyl acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3375 mL | 11.6877 mL | 23.3754 mL | |
| 5 mM | 0.4675 mL | 2.3375 mL | 4.6751 mL | |
| 10 mM | 0.2338 mL | 1.1688 mL | 2.3375 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
